Business
AGM Statement and Q1 Trading Update
AGM Statement and Q1 Trading Update.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n \nRNS Number : 5458X Proteome Sciences PLC 30 April 2019 \n\n30 April 2019\n \n \n \n \n \nProteome Sciences plc\n(\"Proteome Sciences\" or the \"Company\") \n \nAnnual General Meeting (AGM) Statement and Q1 Trading Update\n \nAt the Company's AGM being held today at 2.30 pm the Chairman, Christopher Pearce, will make the following statement:\n \n \"As indicated in our recent results, we remain optimistic about the future, with the near-term availability of higher-plex TMT® set to add significant value to this asset, and the utility of quantitative proteomics increasing in response to diagnostic advances and disruptive technologies. We are pleased to report a good first quarter, with further growth in sales and royalties from TMT® and an improving services business continuing the trend in orders and revenues established during the latter part of 2018.\" \n \n \nFor further information:\n \n\n\n\nProteome Sciences plc \n\n\n\n\nDr Jeremy Haigh, Chief Executive Officer \n\n\nTel: +44 (0)20 7043 2116\n\n\n\n\nDr Ian Pike, Chief Scientific Officer\nRichard Dennis, Chief Commercial Officer\n\n\n\n\n\n\n\n\n \nAllenby Capital Limited (AIM Nominated Adviser & Broker) \n\n\n\n\nJohn Depasquale / Jeremy Porter \n\n\nTel: +44 (0) 20 3328 5656\n\n\n\nAbout Proteome Sciences plc. (www.proteomics.com)\nProteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.\nThe Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.\n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority t...